Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Haiti, the market for bronchodilator drugs is developing in a certain way due to several factors.
Customer preferences: Customers in Haiti prefer affordable and accessible medications. They are price-sensitive and tend to choose generic drugs over branded ones. This is because generic drugs are cheaper and more widely available. In addition, customers prefer inhalers over nebulizers due to their convenience and ease of use.
Trends in the market: The market for bronchodilator drugs in Haiti is growing due to the increasing prevalence of respiratory diseases in the country. This is due to several factors such as air pollution, smoking, and poor living conditions. As a result, there is a higher demand for bronchodilator drugs in the country. In addition, there is a growing trend towards the use of combination bronchodilator drugs, which are more effective in treating respiratory diseases.
Local special circumstances: Haiti is a low-income country with a high burden of disease. The healthcare system in the country is underdeveloped, and access to healthcare is limited. This has resulted in a high prevalence of respiratory diseases, which has led to an increased demand for bronchodilator drugs. However, the availability of these drugs is limited, and many people in the country do not have access to them.
Underlying macroeconomic factors: Haiti is one of the poorest countries in the world, with a low GDP per capita and high levels of poverty. The healthcare system in the country is underfunded and underdeveloped, which has resulted in a lack of access to healthcare for many people. In addition, the country has a high burden of disease, which has put a strain on the healthcare system. These underlying macroeconomic factors have contributed to the development of the bronchodilator drugs market in Haiti.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
